Molecular Templates, Inc.

45 articles with Molecular Templates, Inc.

• Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

  8/6/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2020.

• Molecular Templates, Inc. Raises $43 Million in Gross Proceeds Through Its At-the-Market Facility

  7/20/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it has raised gross proceeds of approximately $43 million through its At-the-Market facility (“ATM”) with participation based on interest received from Consonanc

• Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2020 Highlight Evolution of ETB Platform

  6/22/2020

  Update Provided Phase I Study of MT-5111 in HER2-positive Cancers Conference Call and Webcast to Discuss AACR Posters on June 25th at 10:30am Eastern Time

• New Data on Molecular Templates’ Engineered Toxin Bodies to be Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II

  5/15/2020

  Abstracts feature data on ETBs against clinically validated targets including PD-L1, CTLA-4, SLAMF7 and CD45

• Molecular Templates to Participate in Two May 2020 Virtual Investor Conferences

  5/13/2020

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, announced that management will participate in the Bank of America Securities Virtual Healthcare Conference and the UBS Virtual Healthcare Conference.

• Molecular Templates, Inc. Reports First Quarter 2020 Financial Results

  5/11/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2020.

• Molecular Templates, Inc. Announces that the 2020 Annual Meeting of Stockholders Will be Held in Virtual Format

  5/7/2020

  Molecular Templates, Inc. announced that the 2020 Annual Meeting of Stockholders will be held virtually due to the public health impact of the novel coronavirus outbreak and to support the health and well-being of the Company’s management and stockholders.

• Molecular Templates, Inc. Reports Fourth Quarter 2019 Financial Results

  3/12/2020

  Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies, reported financial results for the fourth quarter of 2019.

• Molecular Templates to Present at Three March Investor Conferences

  2/28/2020

  Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that management will present a corporate overview at the Cowen & Company 40th Annual Health Care Conference,

• 

  Clinical Catch-Up: February 17-21

  2/24/2020

  Mid-February had a solid number of clinical trial announcements. Here’s a look.

• Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple MyelomaMilestone Triggers $10 Million Payment to Molecular Templates

  2/19/2020

  AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced the initiation of dosing in a Phase I study investigating TAK-169 in patients with relapsed/refractory multiple myel

• Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

  1/8/2020

  Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships

• Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

  12/19/2019

  Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, announced today the appointment of Corazon “Corsee” Dating Sanders, Ph.D. to its board of directors, effective immediately.

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
• 

  ASH Roundup: Bristol-Myers Squibb, bluebird bio, Oryzon and More

  12/10/2019

  As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.

• Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

  12/9/2019

  Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, today announced the presentations of two posters on its pipeline programs at the American Society of Hematology (ASH) 2019 Annual Meeting, taking place December 7-10, 2019 in Orlando, Florida

• Molecular Templates to Present at Two December 2019 Investor Conferences

  11/26/2019

  Molecular Templates, Inc. announced that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Evercore ISI HealthCONx Conference, and the Piper Jaffray 31st Annual Healthcare Conference.

• Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

  11/21/2019

  Molecular Templates, Inc. announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share.

• Molecular Templates, Inc. Announces Proposed Public Equity Offering

  11/20/2019

  Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock.

• Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

  11/18/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001.